Oral Semaglutide (Wegovy Pill) - FDA Approved December 2025: According to the OASIS 4 trial published in the New England Journal of Medicine, participants who took the Wegovy pill experienced 13.6% mean weight loss over approximately 64 weeks when including all participants regardless of adherence, compared to 2.2% for those taking placebo
Originally licensed in the UK for the treatment of type 2 diabetes, Ozempic (semaglutide) has become widely known for its weight loss benefits, and its now a subject of much interest among patients struggling with obesity or long-term weight management
T2D and its complications pose a significant burden to public health and the economy
Cho SK, Kim CO, Park ES, et al
This is one super yummy bean dish
It presents as a cluster of changes that often get attributed to "just getting older." Here's what to look for: Persistent Fatigue Not regular tiredness a fundamental lack of energy that doesn't improve with adequate sleep